Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Ergänzendes gezieltes Temperaturmanagement bei akuter schwerer Kohlenmonoxidvergiftung

8. November 2026 aktualisiert von: Yong Sung Cha, Wonju Severance Christian Hospital

Gezieltes Temperaturmanagement kombiniert mit hyperbarer Sauerstofftherapie bei akuter schwerer Kohlenmonoxidvergiftung: Multizentrische randomisierte kontrollierte klinische Studie (TTM-COHB-Studie)

This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.

Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

39

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Gangwon-do
      • Wŏnju, Gangwon-do, Südkorea, 26426
        • Wonju Severance Christian Hospital
    • Incheon
      • Incheon, Incheon, Südkorea, 22332
        • Inha University Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

19 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • ≥ 19 years.
  • Patients who received HBO within 24 hours for acute CO poisoning.
  • Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
  • Signed informed consent prior to study entry.

Exclusion Criteria:

  • Cardiac arrest before HBO
  • Previous neurocognitive disorders
  • Life-threatening underlying disease (ex: advanced cancer)
  • Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
  • Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
  • No admission
  • The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
  • Pregnancy
  • Burns
  • More than moderate burn or Inhalation burn
  • Burns complicated by other trauma
  • Electrical burn
  • Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Hypothermia group

Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Aktiver Komparator: Normothermia group

For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Main neurocognitive outcome
Zeitfenster: At 6 months after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 6 months after CO poisoning

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Neurocognitive outcome
Zeitfenster: At 1 month after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 1 month after CO poisoning
Cerebral Performance Category
Zeitfenster: At 1 month and 6 months after CO poisoning

Cerebral Performance Category [range 1 - 5 (worst score)]

At 1 month and 6 months after CO poisoning
modified Rankin scale
Zeitfenster: At 1 month and 6 months after CO poisoning

modified Rankin scale [range 0 - 6 (worst score)]

At 1 month and 6 months after CO poisoning
Glasgow outcome scale
Zeitfenster: At 1 month and 6 months after CO poisoning

Glasgow outcome scale [range 1 (worst score) - 5]

At 1 month and 6 months after CO poisoning
mini-mental status exam
Zeitfenster: At 1 month and 6 months after CO poisoning

mini-mental status exam

At 1 month and 6 months after CO poisoning
Korean version of the Modified Barthel Index
Zeitfenster: At 1 month and 6 months after CO poisoning

Korean version of the Modified Barthel Index

At 1 month and 6 months after CO poisoning
Mortality in intensive care unit
Zeitfenster: Through study completion, an average of 6 months

Number of participants with mortality in intensive care unit

Through study completion, an average of 6 months
Mortality in intensive care unit
Zeitfenster: Through study completion, an average of 6 months

Rate of participants with mortality in intensive care unit

Through study completion, an average of 6 months
In-hospital mortality
Zeitfenster: Through study completion, an average of 6 months

Number of participants with in-hospital mortality

Through study completion, an average of 6 months
In-hospital mortality
Zeitfenster: Through study completion, an average of 6 months

Rate of participants with in-hospital mortality

Through study completion, an average of 6 months
Mortality
Zeitfenster: At 1, 3, and 6 months after CO poisoning

Number of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Mortality
Zeitfenster: At 1, 3, and 6 months after CO poisoning

Rate of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Length of stay in intensive care unit and hospital
Zeitfenster: Through study completion, an average of 6 months

Length of stay in intensive care unit and hospital

Through study completion, an average of 6 months
Pneumonia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Pneumonia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
Zeitfenster: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
S100ß (serum)
Zeitfenster: Within 14 days after CO exposure

Concentration of S100ß (serum)

Within 14 days after CO exposure
Neuronal specific enolase (serum)
Zeitfenster: Within 14 days after CO exposure

Concentration of neuronal specific enolase (serum)

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
Zeitfenster: Within 14 days after CO exposure

Number of participants with brain injury in brain MRI

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
Zeitfenster: Within 14 days after CO exposure

Rate of participants with brain injury in brain MRI

Within 14 days after CO exposure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Yong Sung Cha, MD, Wonju Severance Christian Hospital

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

25. Oktober 2021

Primärer Abschluss (Tatsächlich)

7. November 2025

Studienabschluss (Tatsächlich)

7. November 2025

Studienanmeldedaten

Zuerst eingereicht

1. Juli 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. Juli 2021

Zuerst gepostet (Tatsächlich)

26. Juli 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

8. November 2026

Zuletzt verifiziert

1. Juni 2025

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • TTM-COHB trial
  • CR220011 (Andere Kennung: Wonju Severance Christian Hospital)
  • 2021-04-043 (Andere Kennung: Inha University Hospital)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .